-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anamorelin Hydrochloride in Chemotherapy Effects
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anamorelin Hydrochloride in Chemotherapy Effects report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anamorelin Hydrochloride in Chemotherapy Effects Drug Details: Anamorelin hydrochloride (Adlumiz) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anamorelin Hydrochloride in Fatigue
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anamorelin Hydrochloride in Fatigue report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anamorelin Hydrochloride in Fatigue Drug Details: Anamorelin hydrochloride (Adlumiz) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anamorelin Hydrochloride in Cancer Anorexia-Cachexia Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anamorelin Hydrochloride in Cancer Anorexia-Cachexia Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anamorelin Hydrochloride in Cancer Anorexia-Cachexia Syndrome Drug Details: Anamorelin hydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Neratinib in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neratinib in Cervical Cancer Drug Details: Neratinib (Nerlynx) is a member...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYD-4228 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYD-4228 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYD-4228 in Follicular Lymphoma Drug Details: SYD-4228 is under development for the...
-
Product Insights
Chemotherapy Induced Nausea and Vomiting – Drugs In Development, 2023
Global Markets Direct’s, ‘Chemotherapy Induced Nausea and Vomiting - Drugs In Development, 2023’, provides an overview of the Chemotherapy Induced Nausea and Vomiting pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Cancer Anorexia-Cachexia Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Cancer Anorexia-Cachexia Syndrome - Drugs In Development, 2023’, provides an overview of the Cancer Anorexia-Cachexia Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Mycosis Fungoides – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycosis Fungoides - Drugs In Development, 2023’, provides an overview of the Mycosis Fungoides pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycosis Fungoides, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Prader-Willi Syndrome (PWS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) - Drugs In Development, 2023’, provides an overview of the Prader-Willi Syndrome (PWS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Chemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2023’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...